Business Wire

FOURKITES

10.5.2023 08:01:24 CEST | Business Wire | Press release

Share
Supply Chain Visibility Leader FourKites Partners with Gravity Supply Chain Solutions to Provide Real-time, First-Mile Visibility for Global Shipments

Leading supply chain visibility provider FourKites today announced an exclusive partnership with Gravity, maker of an award-winning supply chain management platform for many of the world’s leading shippers and freight forwarders. The partnership will extend the real-time visibility offered by the FourKites® platform to encompass the first mile — from the time an order is placed with a supplier — all the way through to product delivery via a seamless integration with Gravity’s SaaS solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509006269/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Supply Chain Visibility Leader FourKites Partners with Gravity Supply Chain Solutions to Provide Real-time, First-Mile Visibility for Global Shipments (Photo: Business Wire)

The first mile is often the critical link in the supply chain, when raw materials and purchased finished products are shipped from global suppliers to manufacturing and distribution locations. “Last-mile delivery generates a lot of attention and a lot of headlines, and often overshadows the importance of the first mile,” FourKites founder and CEO Mathew Elenjickal says. “If you don’t have sufficient control over your upstream supply chain, everything that comes after the first mile will be less effective.”

Inefficiencies and disruptions in the first mile have significant ramifications on working capital, costs and revenue. Traditionally, companies have attempted to manage the first mile through manual processes, including spreadsheets and phone calls. This cumbersome, disjointed approach results in unpredictability and higher costs. Consequently, shippers lack the visibility to know if they will have sufficient inventory on hand to meet production and/or distribution schedules, and they are unable to collaborate efficiently with their suppliers to ensure material availability and delivery dates.

Gravity’s modern, easy-to-use SaaS solution addresses these issues, offering visibility into and control over the purchase order process — from order creation through changes and fulfillment. This solution will integrate with FourKites’ real-time shipment visibility and order intelligence solutions to ensure that customers have an exception-based, single source of truth for the entire order life cycle. The highly configurable solution, which can be up and running quickly, will provide seamless integration, simpler collaboration and streamlined operations with real-time updates — all in one centralised platform.

“Of any visibility provider on the market, we chose to partner with FourKites because of its deep, trusted relationships with many large Fortune 1000 customers,” said Graham Parker, CEO and founder of Gravity Supply Chain Solutions. “Our partnership will give these brands a seamless, end-to-end picture of their supply chain, so they can react quickly and confidently to any situation. We have been impressed by FourKites’ innovative solutions, its collaborative culture and its impressive track record of delivering value to customers, and we’re thrilled to work together to fortify our efforts and provide a unique offering to the market.”

Founded in 2015, Gravity is headquartered in Singapore, with offices in the United States, the United Kingdom and Hong Kong. The company has rapidly gained traction in the 3PL and freight forwarder space, and counts among its customers the French conglomerate Bolloré SE, Rӧhlig Logistics, Scan Global Logistics and Gebrüder Weiss.

“As FourKites continues to expand into order and inventory management with solutions such as our Order Intelligence Suite, this partnership with Gravity will extend our capabilities even further upstream,” Elenjickal says. “As a result, our customers can be confident that their suppliers will provide the necessary components and parts they expect by the promised date, eliminating the delays, confusion and costs that many people now incorrectly attribute to issues with the last mile.”

About FourKites

Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509006269/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye